Openbookopenbook
Equity
StockUS listing USBRVENASDAQHealthcareDeep Value

Braveheart Bio, Inc. Common Stock(BRVE) Stock Analysis | Healthcare

USD --+0.00%
Reward39Moderate
Risk24Low
25%Data
USD —+0.00 (+0.00%) Previous close · NASDAQ
Market cap 1.68Bn
Reward Ratingⓘ39 Moderate reward assessment · 25% data coverage
Bottom 5% of stocksView factors
Risk Ratingⓘ24 Low risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on BRVE to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Braveheart Bio, Inc. Common Stock?

a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases.

AI Brief Pro

The brief on Braveheart Bio, Inc. Common Stock

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Braveheart Bio, Inc. Common Stock?

a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. It develops and offers BHB-1893 and HRS-1893, an oral small-molecule cardiac myosin inhibitor (CMI) for the treatment of obstructive HCM and non-obstructive HCM. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 1.68B.

Financial Highlights

Investment Breakdown

Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
Profitability
Adequate profitability with some margin variability in recent periods.
Risk
Below-average volatility supports a steadier risk profile.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (39)

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

VIRSmall Cap / 1.7B market cap
Vir Biotechnology Inc
Compare
URGNSmall Cap / 1.7B market cap
UroGen Pharma Ltd
Compare
RAPTSmall Cap / 1.7B market cap
RAPT Therapeutics Inc
Compare
Company Information
SectorHealthcare
IndustryBiotechnology
Market Cap1.68B
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Insider Activity
12M windowNo data
No insider activity data available for this ticker.
openbook

Stock research for UK and US investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.